CGEM (Cullinan Therapeutics) Inventories, Raw Materials & Components: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CGEM Cullinan Therapeutics Inc CGEM
22 GF Score
Price $19.52
! 5 Warning Signs
View Full Analysis

What is Cullinan Therapeutics Inventories, Raw Materials & Components?

Cullinan Therapeutics CGEM +6.61% 22 Inventories, Raw Materials & Components is $0.00 Mil as of Jun. 2026. GuruFocus rates CGEM with a GF Score™ of 22/100. The stock has 5 warning signs investors should review.

Cullinan Therapeutics's inventories, raw materials & components for the quarter that ended in Jun. 2026 was $0.00 Mil.

Cullinan Therapeutics Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Cullinan Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cullinan Therapeutics Inventories, Raw Materials & Components Chart

Cullinan Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Cullinan Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CGEM
22GF Score
Cullinan Therapeutics Inc CGEM
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cullinan Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of $0.00 Mil mean?
Cullinan Therapeutics (CGEM) has a Inventories, Raw Materials & Components of $0.00 Mil as of Jun. 2026. Raw materials are the components a company uses for its main products. View historical data on Cullinan Therapeutics and its competitors.
Is Cullinan Therapeutics' Inventories, Raw Materials & Components too high?
Cullinan Therapeutics' current Inventories, Raw Materials & Components is $0.00 Mil. Overall, Cullinan Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Cullinan Therapeutics' Inventories, Raw Materials & Components compare to VOR and ANRO?
Cullinan Therapeutics' Inventories, Raw Materials & Components of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Cullinan Therapeutics and its competitors. Cullinan Therapeutics's current Inventories, Raw Materials & Components is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cullinan Therapeutics stock overvalued right now?
Cullinan Therapeutics (CGEM) has a current Inventories, Raw Materials & Components of $0.00 Mil. The current Inventories, Raw Materials & Components is $0.00 Mil. Cullinan Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Cullinan Therapeutics (CGEM), the current Inventories, Raw Materials & Components is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cullinan Therapeutics Business Description

Address One Main Street, Suite 1350, Cambridge, MA, USA, 02142
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
22GF Score

Get the complete analysis for CGEM

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.52
Price